Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.
Targeted Thearpies in Biliary Tract Cancer
Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.
Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.